Last reviewed · How we verify
Caricide (DIETHYLCARBAMAZINE)
Caricide (Diethylcarbamazine) is a small molecule anthelmintic drug developed by Lederle, targeting Arachidonate 5-lipoxygenase. It is FDA-approved for treating various filarial infections, eosinophilic asthma, and infections caused by Loa loa and Onchocerca volvulus. As an off-patent medication, Caricide is not commercially available as a generic version. Key safety considerations include potential allergic reactions and exacerbation of certain conditions. Caricide has been approved since 1950 and is currently owned by Lederle.
At a glance
| Generic name | DIETHYLCARBAMAZINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Anthelmintic |
| Target | Arachidonate 5-lipoxygenase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Bancroft's Filariasis
- Eosinophilic asthma
- Infection by Loa loa
- Infection by Onchocerca volvulus
- Lymphatic filariasis
Common side effects
Key clinical trials
- Host Response to Infection and Treatment in Filarial Diseases
- Moxidectin for LF, Cote d'Ivoire (DOLF) (PHASE3)
- Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
- Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa (NA)
- Safety and Efficacy of IDA for Onchocerciasis (PHASE2)
- Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa (PHASE2)
- Lymphatic Filariasis (LF) in Ivory Coast (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caricide CI brief — competitive landscape report
- Caricide updates RSS · CI watch RSS
- Pfizer portfolio CI